WARF ADVANCES
Top licensing prospects from the University of Wisconsin-Madison
Simplifying the Process for Early Detection, Screening of Cancer
A pair of surgery researchers developed a diagnostic that allows at-home collection of blood samples, making the early screening and detection of cancer easier and more cost effective and improving health equity for millions of individuals.
Watch
Biomimetic, Reactive Oxygen Species-Detonable Nanoclusters For Antirestenotic Therapy
This multimodal nanocluster drug delivery particle for treating restenosis features greater lesion targetability, improved biodistribution and deeper penetration into injured vessel walls as compared to a conventional PLGA nanoparticle.
Read more
Innovative Screening Tool Better Detects Likelihood of Age-Related Diseases
The tool uses biomarkers derived from CT scans to capture the intricate interplay between genetic factors, lifestyle choices and environmental influences that contribute to biological age, and offers a personalized, precise measure of a patient’s physiological health.
Watch
Ferritin-Targeting PROTACs and Methods of Inducing Pyroptosis
These ferritin-targeting PROTACs establish an iron excess stress inside cancer cells. They substantially inhibited tumor growth and prolonged the survival time of mice bearing B16F10 subcutaneous tumors with negligible adverse effects.
Read more
New Way to Measure Arterial Stiffness Leads to Better Blood Pressure Treatment Plans
This clinical test differentiates between the two main mechanisms behind arterial stiffness – structural stiffness and load-bearing stiffness – which respond differently to available therapies.
Watch
Preventing Adverse Pregnancy Outcomes Due to Use of SSRIs During Gestation
UW-Madison researchers discovered methods for alleviating the adverse effects of selective serotonin reuptake inhibitors (SSRIs) in pregnancy through co-administration of the known drug ketanserin.
Read more
Read about more licensing prospects!
Featured UW-Madison Researcher
 |
Jacques Galipeau, Professor of Oncology
“Jacques is an internationally recognized expert in translational development of cellular pharmaceuticals who has experience with clinical trials. I’m excited about his advances in personalized cell therapies.” – Andy DeTienne, WARF Director of Licensing |
In the News